Page last updated: 2024-08-21

isoxazoles and bortezomib

isoxazoles has been researched along with bortezomib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chaudhry, V; Umapathi, T1
Andrulis, M; Bargou, RC; Beilhack, A; Bogen, B; Bumm, T; Chatterjee, M; Einsele, H; Heimberger, T; Riedel, S; Schraud, H; Stühmer, T1
Chen, JS; Cheng, DR; Ji, SM; Li, X; Liu, ZH; Wen, JQ; Wu, D; Xie, KN; Zhang, MC1
Akimov, M; Alegre, A; Bargou, RC; Bladé, J; Fernandez-Ibarra, C; Goh, YT; Iyer, SP; Lu, H; Ottmann, OG; Pain, S; Seggewiss-Bernhardt, R; Spencer, A; Stewart, AK1
Furie, R; Toder, K; Zapantis, E1
Boccarelli, A; Cabral, LM; de Pádula, M; Di Mauro, GD; Ferorelli, S; Fortuna, CG; Iaselli, M; Miciaccia, M; Pati, ML; Perrone, MG; Rodrigues Pereira da Silva, LC; Sathler, PC; Scilimati, A; Souza Domingos, TF; Vacca, A; Vitale, P1

Reviews

2 review(s) available for isoxazoles and bortezomib

ArticleYear
Toxic neuropathy.
    Current opinion in neurology, 2005, Volume: 18, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Leflunomide; Neuritis; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Pyridoxine; Thalidomide

2005
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
    Seminars in nephrology, 2015, Volume: 35, Issue:5

    Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Boron Compounds; Bortezomib; Clinical Trials as Topic; Drug Discovery; Glycine; Humans; Immunologic Factors; Immunosuppressive Agents; Infliximab; Isoxazoles; Leflunomide; Lupus Nephritis; Mycophenolic Acid; Off-Label Use; Oligonucleotides; Quinolones; Recombinant Fusion Proteins; Rituximab; Tacrolimus; Treatment Outcome

2015

Trials

1 trial(s) available for isoxazoles and bortezomib

ArticleYear
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
    Cancer, 2015, Jul-01, Volume: 121, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Multiple Myeloma; Resorcinols

2015

Other Studies

3 other study(ies) available for isoxazoles and bortezomib

ArticleYear
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
    British journal of haematology, 2013, Volume: 160, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Diterpenes; DNA-Binding Proteins; Down-Regulation; Epoxy Compounds; Female; Gene Knockdown Techniques; Heat Shock Transcription Factors; Heat-Shock Proteins; Humans; Immunohistochemistry; Isoxazoles; Mice; Mice, Inbred BALB C; Multiple Myeloma; Neoplasm Transplantation; Phenanthrenes; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Resorcinols; RNA, Small Interfering; Transcription Factors; Transplantation, Heterologous

2013
BK Virus-Associated Nephropathy with Plasma Cell-Rich Infiltrates Treated by Bortezomib-Based Regimen.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2015, Volume: 13, Issue:6

    Topics: Adult; Antineoplastic Agents; BK Virus; Bortezomib; Female; Humans; Isoxazoles; Kidney Diseases; Kidney Transplantation; Leflunomide; Plasma Cells; Polyomavirus Infections; Postoperative Complications; Tacrolimus; Tumor Virus Infections

2015
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Multiple Myeloma; Platelet Aggregation Inhibitors; Protein Binding; Structure-Activity Relationship

2019